First-in-human study of HMPL-295, an ERK1/2 inhibitor, in patients with advanced solid tumors: Dose-escalation results of monotherapy

被引：0
|
作者：
Yu, Xianjun
Zhang, Jian
Sun, Yuping
Deng, Yanhong
Guo, Shuangshuang
Hong, Wei
Shi, Si
Liu, Rujiao
Gao, Shuiping
Dang, Qi
Zhang, Jianwei
Su, Weiguo
Shi, Michael
Fan, Songhua
Zhang, Bo
Pan, Beiqing
Jia, Xiaoyun
Wang, Jian
Zhong, Chen
Ma, Luguang
机构：
[1] Fudan Univ, Dept Pancreat Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Shandong Canc Hosp, Jinan, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou, Peoples R China
[5] Henan Univ Sci & Technol, Dept Med Oncol, Affiliated Hosp 1, Luoyang, Peoples R China
[6] Zhejiang Canc Hosp, Dept Thorac Med Oncol, Hangzhou, Peoples R China
[7] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat Hepatobiliary Surg, Shanghai, Peoples R China
[8] Fudan Univ, Phase 1 Clin Trial Ctr, Shanghai Canc Ctr, Shanghai, Peoples R China
[9] Shandong Canc Hosp, Jinan, Shandong, Peoples R China
[10] HUTCHMED Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15112
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
    Yu, X.
    Zhang, J.
    Liu, R.
    Deng, Y.
    Cai, Y.
    Sun, Y.
    Dang, Q.
    Hong, W.
    Song, Z.
    Guo, S.
    Gao, S.
    Su, W.
    Shi, M.
    Fan, S.
    Zhang, B.
    Pan, B.
    Ren, Y.
    Wang, J.
    Zhong, C.
    Ma, L.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1496 - S1497
  • [2] Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors
    Wahlroos, Sara
    Teng, Christina
    Tran, Ben
    Voskoboynik, Mark
    Gan, Hui Kong
    Spencer, Andrew
    Kudva, Anupa
    Song, Ming
    Lynch, Kevin
    Yu, Zhinuan
    Desai, Jayesh
    Lemech, Charlotte Rose
    Lifehouse, Chris O'Brien
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Infante, Jeffrey R.
    Mendelson, David S.
    Burris, Howard A., III
    Bendell, Johanna C.
    Tolcher, Anthony W.
    Gordon, Michael S.
    Gillenwater, Heidi H.
    Arastu-Kapur, Shirin
    Wong, Hansen L.
    Papadopoulos, Kyriakos P.
    [J]. INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 216 - 224
  • [4] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Jeffrey R. Infante
    David S. Mendelson
    Howard A. Burris
    Johanna C. Bendell
    Anthony W. Tolcher
    Michael S. Gordon
    Heidi H. Gillenwater
    Shirin Arastu-Kapur
    Hansen L. Wong
    Kyriakos P. Papadopoulos
    [J]. Investigational New Drugs, 2016, 34 : 216 - 224
  • [5] A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
    Carducci, Michael A.
    Wang, Ding
    Habermehl, Christina
    Bodding, Matthias
    Rohdich, Felix
    Lignet, Floriane
    Duecker, Klaus
    Karpenko, Oleksandr
    Pudelko, Linda
    Gimmi, Claude
    LoRusso, Patricia
    [J]. CANCER RESEARCH COMMUNICATIONS, 2023, 3 (08): : 1638 - 1647
  • [6] A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors
    Pant, Shubham
    Burris, Howard A., III
    Moore, Kathleen
    Bendell, Johanna C.
    Kurkjian, Carla
    Jones, Suzanne F.
    Moreno, Ofir
    Kuhn, John G.
    McMeekin, Scott
    Infante, Jeffrey R.
    [J]. INVESTIGATIONAL NEW DRUGS, 2014, 32 (01) : 87 - 93
  • [7] First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors
    Azaro, A.
    Rodon, J.
    Herranz, M.
    Nuciforo, P.
    Prudkin, L.
    Lopez-Busto, N.
    Balandraud, S.
    Cattan, V.
    Jacquet-Bescond, A.
    Marfai, L.
    Pauly, J.
    Postel-Vinay, S.
    Hollebecque, A.
    Soria, J. C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S54 - S54
  • [8] A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors
    Shubham Pant
    Howard A. Burris
    Kathleen Moore
    Johanna C. Bendell
    Carla Kurkjian
    Suzanne F. Jones
    Ofir Moreno
    John G. Kuhn
    Scott McMeekin
    Jeffrey R. Infante
    [J]. Investigational New Drugs, 2014, 32 : 87 - 93
  • [9] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Mathiot, Laurent
    Combarel, David
    Cagnat, Justin
    Delahousse, Julia
    Ouali, Kaissa
    Marabelle, Aurelien
    Loriot, Yohann
    Ponce, Santiago
    Champiat, Stephane
    Broutin, Sophie
    Danlos, Francois-Xavier
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [10] First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
    Sullivan, Ryan J.
    Infante, Jeffrey R.
    Janku, Filip
    Wong, Deborah Jean Lee
    Sosman, Jeffrey A.
    Keedy, Vicki
    Patel, Manish R.
    Shapiro, Geoffrey I.
    Mier, James W.
    Tolcher, Anthony W.
    Wang-Gillam, Andrea
    Sznol, Mario
    Flaherty, Keith
    Buchbinder, Elizabeth
    Carvajal, Richard D.
    Varghese, Anna M.
    Lacouture, Mario E.
    Ribas, Antoni
    Patel, Sapna P.
    DeCrescenzo, Gary A.
    Emery, Caroline M.
    Groover, Anna L.
    Saha, Saurabh
    Varterasian, Mary
    Welsch, Dean J.
    Hyman, David M.
    Li, Bob T.
    [J]. CANCER DISCOVERY, 2018, 8 (02) : 184 - 195
12345